Testing erugliflozin for fatty liver and diabetes control
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a written consent form and are willing to join the study
- You’re between 18 and 65 years old
- You have type 2 diabetes and you have not used insulin or SGLT2 inhibitor medicines before
- Your body mass index (BMI) is over 23
- Your blood sugar marker (HbA1c) is between 6.5% and 10%
- Your ultrasound shows fatty liver (liver steatosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study tests whether a class of diabetes drugs called SGLT2 inhibitors can help reduce fat in the liver for people with type 2 diabetes and chronic kidney disease. If you have both conditions, this treatment might improve your liver health.
This study tests whether a medicine called empagliflozin (a type of SGLT2 inhibitor) can help treat non-alcoholic fatty liver disease in adolescents with obesity. It aims to see if the drug can reduce fat in the liver and improve liver health.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
Hear when a new Liver Fat trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.